English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Since the first reported use of percutaneous transluminal coronary angioplasty (PTCA), advances in the interventional cardiology arena have been fast-paced. Within the last 10 years, these developments have been exponential. Developers and clinicians are fast adapting from the learning curve awarded by the time-course of drug-eluting stent (DES) evolution. The BioMime™ sirolimus-eluting coronary stent is a new step towards a biomimicry concept. The stent is built on an ultra-low strut thickness (65µm) cobalt–chromium stent platform using an intelligent hybrid of close and open cells allowing for morphology-mediated expansion, and employs a well-known antiproliferative – sirolimus – that elutes from a biodegradable co-polymer formulation in 30 days and ensures high coating integrity and a low coating thickness of 2µm. The resultant stent demonstrated almost 100% endothelialisation at 30 days in pre-clinical models and 0% major adverse cardiac events (MACE) at six months in the primary efficacy and safety clinical study.

Moving Towards Biomimicry – The Development of the Novel BioMime™ Sirolimus-eluting Coronary Stent System